Travere Therapeutics Inc Forecast, price target & analysts
Travere Therapeutics Inc Target price 2024 - Analyst rating & recommendation
Travere Therapeutics Inc Classifications & Recommendation:
Travere Therapeutics Inc Target price
| Target price | $14.86 |
| Course | $8.22 |
| Price potential |
80.75%
register free of charge
|
| Number of estimates | 15 |
|
15 Analysts have issued a price target Travere Therapeutics Inc 2025 .
The average Travere Therapeutics Inc target price is $14.86.
This is
80.75%
register free of charge
$20.00
143.31%
register free of charge
$9.00
9.49%
register free of charge
|
|
| A rating was issued by 16 analysts: 11 Analysts recommend Travere Therapeutics Inc to buy, 5 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst estimates: Analysts believe that the Travere Therapeutics Inc share has an average upside potential 2025 of
80.75%
register free of charge
|
Sales and margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Turnover Million $ | 145.24 | 215.00 |
| 31.50% | 48.03% | |
| EBITDA margin | -232.86% | -106.01% |
| 125.98% | 54.48% | |
| Net margin | -237.91% | -120.09% |
| 51.66% | 49.52% |
13 Analysts have issued a sales forecast Travere Therapeutics Inc 2024 . The average Travere Therapeutics Inc sales estimate is
This results in the following potential growth figures:
4 Analysts have issued an Travere Therapeutics Inc EBITDA forecast 2024. The average Travere Therapeutics Inc EBITDA estimate is
This results in the following potential growth figures and future EBITDA margins:
15 Travere Therapeutics Inc Analysts have issued a net profit forecast 2024. The average Travere Therapeutics Inc net profit estimate is
This results in the following potential growth figures and future net margins:
Earnings per share, P/E ratio and EV/sales forecast 2024, 2025 to 2028
| Dec '23 |
2024 Forecast |
|
|---|---|---|
| Earnings per share $ | -4.54 | -3.39 |
| 3.89% | 25.33% | |
| P/E ratio | negative | |
| EV/Sales | 2.74 |
15 Analysts have issued a Travere Therapeutics Inc forecast for earnings per share. The average Travere Therapeutics Inc <a href=/blog/eps>EPS is
This results in the following potential growth figures and future valuations:
Based on analysts' sales estimates for 2024, the Travere Therapeutics Inc share is valued at an <a href=/blog/ev-sales-einfach-erklaert>EV/Sales of
This results in the following potential growth figures and future valuations:
Travere Therapeutics Inc...
Discover more stocks with a high price target
Register for free
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.
